New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
06:08 EDTDVAXDynavax initiates Phase 3 study of HEPLISAV-B
Dynavax Technologies announced initiation of a new phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine. This large safety and immunogenicity study, known as HBV-23, was designed to address the Complete Response Letter regarding the HEPLISAV-B Biologics License Application that was issued to Dynavax by the FDA in February, 2013. HBV-23 will provide greater clarity regarding the safety profile of HEPLISAV-B by significantly expanding the overall database of vaccinated subjects. The study will also assess the immunogenicity of HEPLISAV-B in subjects for whom approved hepatitis B vaccines are less effective. Dynavax expects that all study subjects will be enrolled by the end of 2014 and all follow-up will be completed by 4Q15.
News For DVAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 23, 2015
10:00 EDTDVAXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:23 EDTDVAXDynavax upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Dynavax to Overweight saying it is now "significantly more comfortable" with the safety of the company's Heplisav vaccine for hepatitis B. The firm raised its price target for shares to $36 from $15.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use